What is CGTX (CGTX) stock price today?

CGTX (CGTX) is currently trading at $1.05, up 3.96% today.

What is CGTX P/E ratio?

CGTX's P/E ratio is -3.94. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is CGTX return on equity (ROE)?

CGTX's return on equity (ROE) is -67.65%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is CGTX's market cap?

CGTX has a market capitalization of $93.97M.

NASDAQ · Biotechnology

CGTX (CGTX) Stock

$1.05 +3.96% NASDAQ: CGTX Healthcare

Valuation

Metric	Value
Price	$1.05
Market Cap	$93.97M
P/E Ratio	-3.94
P/B Ratio	2.73
P/S Ratio	0.00
EPS (TTM)	$0.00
52-Week High	$3.83
52-Week Low	$0.25
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-67.65%
ROA	-47.92%
ROCE	-141.18%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.02
Current Ratio	3.43

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-29.0M	$-44.0M	$-51.0M	$-54.0M	$-48.0M
Net Profit	$-12.0M	$1.0M	$-26.0M	$-34.0M	$-23.0M
EPS	$-0.73	$-0.74	$-0.86	$-0.85	$-0.32
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$59.0M	$50.0M	$35.0M	$30.0M	$48.0M
Total Liabilities	$8.0M	$10.0M	$11.0M	$11.0M	$14.0M
Cash	$55.0M	$42.0M	$30.0M	$25.0M	$37.0M
Borrowings	$0	$1.0M	$1.0M	$1.0M	$1.0M

Latest News

Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit GlobeNewswire · Jul 13, 2026 Cognition Therapeutics Gets Positive FDA Feedback Over Phase 3 Study Of DLB Psychosis – But CGTX Stock Just Crashed 33% Stocktwits · Jun 24, 2026 Cognition Therapeutics Advances After FDA Supports Key Elements of Pivotal Trial Plan (CGTX) InvestorsHub · Jun 24, 2026 Cognition Therapeutics Agrees With FDA on Phase 3 Trial Framework for Psychosis Treatment MT Newswires · Jun 24, 2026 Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes GlobeNewswire · Jun 24, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-4.0M	$-19.0M	$-16.0M	$-28.0M	$-25.0M
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$9.0M	$2.0M	$0	$0	$0
Net Cash Flow	$50.0M	$-13.0M	$-12.0M	$-5.0M	$12.0M
Free Cash Flow	$-4.0M	$-19.0M	$-16.0M	$-28.0M	$-25.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-21.84%
Quick Ratio	5.92
Interest Coverage	—
Return 1Y	65.49%
Return 3Y	-45.66%
Return 5Y	—

Ownership

Insiders Held1.37%

Institutions Held25.02%

Institutions Float Held25.36%

Institutional Holder	Shares	Report Date
Bios Capital Management, LP	6,000,000	2026-03-31
Davenport & Co LLC	4,259,511	2026-06-30
Vanguard Capital Management LLC	3,001,787	2026-03-31
Renaissance Technologies, LLC	1,117,136	2026-03-31
Chescapmanager LLC	997,029	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AGEN	$8.09	+1.25%	3.04	$336.89M	0.00%
ATOS	$2.46	+1.65%	-1.23	$24.54M	0.00%
GLSI	$15.74	+4.86%	-21.98	$231.03M	0.00%
IRD	$4.45	+16.19%	-3.50	$367.42M	0.00%
MCRB	$5.54	+6.95%	11.97	$53.65M	0.00%

About CGTX

CGTX is led by CEO Lisa Ricciardi, employs 25 people, headquartered in US, publicly traded since 2021.

CGTX stock trades at $1.05 with a market capitalization of $93.97M. The stock is valued at a price-to-earnings (P/E) ratio of -3.94, price-to-book of 2.73, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.25 and $3.83, and currently trades 72.6% below its 52-week high.

On profitability, CGTX generates a return on equity (ROE) of -67.65%, return on capital employed of -141.18%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides